EMA oncology updates raise the bar for comparative-evidence planning in antibody-drug conjugates

Recent EMA oncology communications reinforce the need for clear evidence logic when direct head-to-head data are limited. This brief outlines practical implications for Health Technology Assessment submissions and comparative-evidence framing.